MedTrace Logo

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

NCT06788171 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-01-23

No results posted yet for this study

Summary

To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM

Conditions

  • Colorectal Cancer Liver Metastasis

Interventions

RADIATION

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy

PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.

DRUG

Bevacizumab

Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.

DRUG

Capecitabine

Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.

DRUG

Sintilimab

Sintilimab: 200mg, d1, q3w, 6 cycles.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-12-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06788171 on ClinicalTrials.gov